Hydrophilic somatostatin analogs

• US 6,465,613 B1
• Filed: 11/19/1998
• Issued: 10/15/2002
• Est. Priority Date: 11/19/1998
• Status: Expired due to Fees

• Current Assignee: Tulane University
• Original Assignee: Tulane University
• Inventors: Murphy, William A., Fuselier, Joseph A., Drouant, George, Woltering, Eugene A., Coy, David H.
• Primary Examiner(s): BORIN, MICHAEL L
• Application Number:
  US09/196,259
• Time in Patent Office: 1,426 Days
• Field of Search: 530/311, 530/300, 530/329, 530/327, 424/1.11, 424/1.69, 514/14, 514/15, 514/5
• US Class Current: 530/311
• CPC Class Codes: A61K 2123/00 Preparations for testing in vivo
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/655 Somatostatins

Abstract

The invention features novel somatostatin analogs that may be readily labeled with toxic or non-toxic detectable labels. These unlabeled and labeled analogs are useful for specifically targeting somatostatin receptor bearing cells, in particular neoplastic cells. Labeled analogs are useful, for example, for tumor localization and detection. Where labeled with a toxic label (e.g., radioactivity), the analogs are useful for the targeted delivery of toxicity to somatostatin receptor-bearing cells, in particular neoplastic cells.

Also disclosed are methods for treating and detecting neoplasms, and methods for imaging somatostatin receptor-bearing cells.

Claims

1. A compound comprising a somatostatin analog of the formula:

2. The analog of claim 1, wherein said analog is attached to a detectable label.

3. The analog of claim 2, wherein said detectable label is toxic.

4. The analog of claim 2, wherein said detectable label is non-toxic.

5. The analog of claim 2, wherein said analog is indirectly attached to said detectable label.

6. The analog of claim 5, wherein said analog is attached to a chelating group that is attached to said detectable label.

7. The analog of claim 2, wherein said analog is directly attached to said detectable label.

8. The analog of claim 2, wherein said detectable label is an iodine label that is attached to a tyrosine residue or a phenylalanine residue of said analog.

9. The analog of claim 3, wherein said toxic detectable label is radioactive.

10. The analog of claim 8, wherein said analog comprises a tyrosine residue.

11. The analog of claim 10, wherein said iodotyrosine residue of said analog does not undergo enzymatic deiodination.

12. The analog of claim 1, wherein said analog has a biological activity that is greater than or equal to the biological activity of the somatostatin peptide of said analog.

13. A method of selectively targeting and arresting the growth of an angiogenic blood vessel or a cell thereof in a subject, said method comprising administering a somatostatin analog of claim 1 to said subject.

14. Pharmaceutical composition comprising compound of claim 1 and a pharmaceutically acceptable carrier.

15. A method for treating or alleviating a neoplasm in an animal, said method comprising the steps of:

(a) providing an animal comprising a somatostatin receptor-bearing neoplastic cell;

(b) providing a somatostatin analog of claim 1, wherein said somatostatin analog specifically binds to said somatostatin receptor; and

(c) administering a neoplastic cell growth-arresting amount of said somatostatin analog to said animal.

16. A method for treating or alleviating a neoplasm in an animal, said method comprising the steps of:

(a) providing an animal comprising a somatostatin receptor-bearing neoplastic cell;

(b) providing a somatostatin analog of claim 3, wherein said somatostatin analog specifically binds to said somatostatin receptor; and

(c) administering a neoplastic cell growth-arresting amount of said somatostatin analog to said animal.

17. A method for imaging a somatostatin receptor-bearing cell in an animal, said method comprising the steps of:

(a) providing an animal comprising a somatostatin receptor-bearing cell;

(b) providing a somatostatin analog of claim 2, wherein said somatostatin analog specifically binds to said somatostatin receptor; and

(c) administering said somatostatin analog to said animal, wherein said administration allows for the imaging of said cell.

18. A method for detecting, in an animal, a cell that expresses an abnormally high level of a somatostatin receptor, said method comprising the steps of:

(a) providing an animal comprising a cell expressing an abnormally high level of a somatostatin receptor;

(b) providing a somatostatin analog of claim 2, wherein said somatostatin analog specifically binds to said somatostatin receptor; and

(c) administering said somatostatin analog to said animal, wherein said administration allows for the detection of said cell.

19. The method of claim 15, 16, 17, or 18, wherein said animal is a human.

20. The method of claim 13, 15, 16, 17, 18, wherein said analog is administered with a pharmaceutically-acceptable carrier.